Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements about atorvastatin-associated myopathy/rhabdomyolysis, liver enzyme elevations, monitoring, caution with alcohol/liver disease, and drug interaction classes are supported by the provided label excerpts. However, multiple alcohol-specific risk-increase assertions (synergy/greater chance/greater significance/indirect muscle risk via alcohol-specific mechanisms, binge effects, and older age/liver risk/dose/exposure claims tied to alcohol) are not directly supported in the supplied label text, reducing overall alignment.
Category Scores
Accurate Statements
Statins can rarely cause rhabdomyolysis.
5.1: 'Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR...'
Statins can occasionally cause myopathy (muscle aches or weakness with CPK >10 times ULN).
5.1: 'Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN.'
The risk of myopathy/rhabdomyolysis is increased with concomitant higher doses and certain interacting drugs (including strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and HIV protease inhibitors; and cyclosporine).
5.1: 'The concomitant use of higher doses of atorvastatin with... cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.' plus 7: 'risk... increased with... cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole)'.
Using Lipitor with higher-risk interacting agents increases risk of myopathy/rhabdomyolysis.
5.1: 'risk of myopathy during treatment... is increased with concurrent administration of... cyclosporine... erythromycin, clarithromycin... HIV protease inhibitors... or... azole antifungals.' and 7: general statement.
Liver enzyme (transaminase) elevations are associated with statins/atorvastatin; persistent elevations (>3x ULN on 2+ occasions) occurred in clinical trials (with given incidences).
5.2: 'Statins... have been associated with biochemical abnormalities of liver function' and 'Persistent elevations (>3 times ULN occurring on 2 or more occasions) occurred in 0.7%...'
LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.
5.2: 'LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.'
Active liver disease or unexplained persistent transaminase elevations are contraindications.
5.2: 'Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see Contraindications (4.1)].'
Liver function tests are recommended prior to and at 12 weeks after initiation and after any dose increase, and periodically thereafter; liver enzyme changes generally occur in first 3 months; if ALT/AST >3x ULN persist, dose reduction or withdrawal is recommended.
5.2: 'recommended that liver function tests be performed prior to and at 12 weeks... and periodically (e.g., semiannually) thereafter' and 'Liver enzyme changes generally occur in the first 3 months' and 'Should an increase in ALT or AST of >3 times ULN persist, reduction... or withdrawal... is recommended.'
Unsupported Statements
Heavy alcohol intake can stress the liver.
5.2 supports caution in those consuming substantial quantities of alcohol, but the label excerpt does not explicitly state 'heavy alcohol intake can stress the liver.'
Using Lipitor and heavy alcohol together increases the chance that liver enzymes rise.
Label excerpt supports caution with substantial alcohol, but does not state an interaction that increases the chance of liver enzyme elevations.
Using Lipitor and heavy alcohol together increases the chance that liver problems become more significant.
No explicit label statement in provided text about increased severity/likelihood of liver problems with alcohol plus Lipitor.
The increased liver risk with Lipitor and heavy alcohol is especially significant in people who already have liver disease or who drink heavily.
Label supports caution with substantial alcohol and caution/history of liver disease, and contraindications for active liver disease/unexplained persistent transaminase elevations, but does not quantify 'especially significant' or state increased risk magnitude with the combination.
Alcohol can contribute indirectly to the risk of statin-related muscle injury, particularly with heavy drinking.
Provided skeletal muscle section does not mention alcohol as a contributor to muscle injury risk.
Alcohol can contribute indirectly to the risk of statin-related muscle injury particularly when alcohol use leads to dehydration.
No label support in provided excerpts linking alcohol/dehydration to statin-related myopathy/rhabdomyolysis.
Alcohol can contribute indirectly to the risk of statin-related muscle injury particularly when alcohol use leads to poor nutrition or low activity.
No label support in provided excerpts linking alcohol-related poor nutrition/low activity to statin-related myopathy/rhabdomyolysis.
The risk of liver enzyme elevations or liver problems with Lipitor and alcohol is higher with heavy or binge alcohol use.
Label excerpt only states 'use with caution' in those who consume substantial quantities of alcohol; it does not mention binge alcohol or 'higher risk' with alcohol.
The risk of liver enzyme elevations or liver problems with Lipitor and alcohol is higher with a history of liver disease or abnormal liver tests.
Label excerpt supports caution with history of liver disease and contraindications with active liver disease/unexplained persistent transaminase elevations, but does not explicitly state that the risk is 'higher' when combined with Lipitor.
The risk of liver enzyme elevations or liver problems with Lipitor and alcohol is higher in older age.
Provided label excerpt on geriatric use addresses myopathy risk with advanced age; it does not state older age increases liver enzyme/liver problem risk with alcohol plus Lipitor.
The risk is higher with higher Lipitor doses.
5.2 provides incidences of persistent transaminase elevations by dose (10/20/40/80 mg), but the statement is framed as 'The risk is higher...' specifically in the context of alcohol/Lipitor combined risk; that alcohol linkage is unsupported. Standalone dose-risk is only partially supported.
The risk is higher with other medications that raise statin exposure, such as certain antibiotics, antifungals, or HIV medications.
Label excerpt supports increased myopathy/rhabdomyolysis risk with specific interacting agents (e.g., clarithromycin/erythromycin, azole antifungals, HIV protease inhibitors), but the statement is overly broad ('certain antibiotics/antifungals/HIV medications') without exact label alignment to all mentioned categories. Partial alignment exists, but not fully supported as stated.
Avoiding binge drinking reduces liver and muscle risk compared with small amounts of alcohol.
No label statement about binge drinking comparisons or risk reduction with avoiding binge drinking.
Contradictions
Important Omissions
No statement was included about baseline/12-week and periodic liver function testing recommendations, or the specific threshold for action (ALT/AST >3x ULN persist) when discussing liver enzyme elevations risk with alcohol.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims (myopathy/rhabdomyolysis, liver enzyme elevations, caution with substantial alcohol, monitoring concept omission) are supported, but several alcohol-specific risk-increase and mechanism claims are not supported by the provided label excerpts. Unsupported assertions about increased likelihood/severity and specific mechanisms could mislead risk perception. Medication interaction and geriatric myopathy caution are not accurately tied to alcohol in the label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple alcohol-specific quantitative/causal risk increase and mechanism statements are not supported by the supplied label excerpts, and some assertions improperly extend label caution into stronger 'higher risk' claims (including binge drinking and combined-risk framing).
Suggested Improvement
Rephrase alcohol-related points to match label wording ('use with caution in patients who consume substantial quantities of alcohol') without claiming increased likelihood or mechanisms not present in the provided label text; align dose-related liver enzyme risk with the label’s dose-specific incidence data; avoid binge-specific comparisons unless present; and include the label’s liver function monitoring recommendations/thresholds.